STOCK TITAN

If You Invested in Perceptive Cap (PCSC)

Services-medical Laboratories · Shell Companies · NASDAQ
Looking for the current price? See the PCSC quote & overview
$1,000 invested 1 Year Ago
$1,120
+12.0% total 12.2% CAGR
Bought on Jul 21, 2025 at $10.60
$1,000 invested 5 Years Ago
N/A
Trading since 2024-06-12

What $1,000 or $10,000 in PCSC Would Be Worth Today

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Jun 12, 2024
$1,000 $1,120 +12% $1,181 +18%
$10,000 $11,198 +12% $11,811 +18%

Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for PCSC

$1,000 Investment Over Time

PCSC vs S&P 500

Year-by-Year Returns

PCSC annual performance
Year Start Price End Price Annual Return Cumulative
2024 $10.05 $10.18 +1.3% +1.3%
2025 $10.18 $13.03 +28.0% +29.7%
2026 $13.00 $11.87 -8.7% +18.1%

About Perceptive Cap

Services-medical Laboratories · NASDAQ

Perceptive Capital Solutions Corp (NASDAQ: PCSC) is a special purpose acquisition company (SPAC) classified in the Financial Services sector under shell companies. According to company disclosures, it was formed for the purpose of entering into a combination with one or more businesses or entities, with an intended focus on the healthcare industry in the United States and other developed countries.

PCSC’s sponsor is described as an affiliate of Perceptive Advisors, which is characterized in company materials as a life sciences focused investment firm. The SPAC’s stated objective is to identify and complete an initial business combination, and it has indicated an intention to concentrate on healthcare-related opportunities, even though it may pursue a combination target in any business or industry.

Business purpose and SPAC structure

As a blank check company, Perceptive Capital Solutions Corp does not describe ongoing operating businesses of its own. Instead, its purpose is to raise capital and then merge with or acquire an operating company. In public communications, PCSC has emphasized its focus on partnering with life sciences and healthcare businesses, reflecting the background of its sponsor and management team.

The company’s Class A ordinary shares are listed on The Nasdaq Global Market under the ticker symbol PCSC. Public information notes that the SPAC was formed to pursue a business combination and that it completed an initial public offering of Class A ordinary shares, with Jefferies LLC serving as sole book-running manager for that offering.

Proposed business combination with Freenome

PCSC has announced that it entered into a definitive business combination agreement with Freenome Holdings, Inc., an early cancer detection company developing blood-based screening tests. Under the announced terms, upon closing of the transaction PCSC will redomicile as a Delaware corporation, be renamed Freenome, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol FRNM. The combined entity is referred to in disclosures as the “Combined Company.”

According to the announcement, the proposed transaction involves a combination of funds held in a trust account by PCSC and a concurrent private investment in public equity (PIPE) in common stock. The business combination remains subject to conditions including approval of the stockholders of both Freenome and PCSC and satisfaction or waiver of other conditions stated in the definitive business combination agreement.

Healthcare focus and sponsor background

Company communications state that while PCSC may pursue an initial business combination target in any business or industry, it intends to focus on the healthcare industry in the United States and other developed countries. The sponsor is described as an affiliate of Perceptive Advisors, which is presented as a life sciences focused investment firm. PCSC’s leadership has publicly framed the SPAC as having been founded to partner with transformational life sciences companies, and has cited Freenome as an example of the type of business it set out to support.

Status and trading symbol context

As of the information provided, PCSC trades on Nasdaq under the symbol PCSC and has announced, but not yet completed, a proposed business combination with Freenome. Public statements describe expectations that, upon closing, the combined company will be renamed Freenome, Inc. and is expected to trade under the ticker FRNM. These statements are characterized as forward-looking and remain subject to the risks and uncertainties outlined in the company’s communications and in documents to be filed with the U.S. Securities and Exchange Commission (SEC).

Investor considerations and disclosures

Public materials emphasize that the proposed business combination will be submitted to shareholders of PCSC for their consideration. PCSC has indicated that it intends to file a registration statement on Form S-4 with the SEC, which will include proxy statements and a prospectus relating to the offer of securities to be issued to Freenome’s stockholders in connection with the completion of the proposed business combination. The company has urged shareholders and other interested persons to read these documents when they become available because they will contain important information about PCSC, Freenome and the proposed transaction.

Forward-looking statements in PCSC’s and Freenome’s communications are accompanied by cautionary language noting that actual events and circumstances may differ from expectations. The announcements reference a variety of potential risks and uncertainties related to the ability to consummate the business combination, obtain regulatory approvals, and achieve anticipated benefits, among other factors.

Summary

In summary, Perceptive Capital Solutions Corp (PCSC) is a Nasdaq-listed SPAC in the Financial Services sector. It describes its purpose as entering into a business combination, with a stated focus on healthcare and life sciences opportunities, and has announced a definitive agreement to combine with Freenome Holdings, Inc. Investors and observers use PCSC primarily as a vehicle for exposure to the outcome of this proposed transaction and any resulting combined company, subject to the approvals and conditions described in public filings and announcements.

Market Cap
$0.1B
Current Price
$11.87
View full PCSC overview

Frequently Asked Questions

Perceptive Cap investment returns

How much would $1,000 invested in Perceptive Cap be worth today?

If you invested $1,000 in Perceptive Cap (PCSC) 1 years ago on 2025-07-21, your investment would be worth $1,120 today, representing a +12.0% total return, growing at a compounded rate of 12.2% per year (CAGR).

Has Perceptive Cap outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare PCSC performance over available time periods.

What is Perceptive Cap's average annual return?

The compound annual growth rate (CAGR) of PCSC over the past 1 years is 12.2%, growing at a compounded rate each year. Individual years vary significantly — PCSC's best recent year was 2025 (+28.0%) and worst was 2026 (-8.7%).

Your Privacy is Protected

This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.

Server-Assisted No Saved Calculator Data Historical Market Data

For informational and educational purposes only — not investment advice.